Robots and dye could spare testicular cancer patients unnecessary treatment

NCT ID NCT06133543

Recruiting now Diagnosis Sponsor: Heinrich-Heine University, Duesseldorf Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new, less invasive way to check if testicular cancer has spread. Doctors inject a dye into the testicle, then use a robot to find and remove the first lymph node that drains the tumor. The goal is to see if this method is accurate enough to replace more extensive treatments. The trial will enroll 44 adults with early-stage testicular cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Indocyanine green (ICG) dye
What this could lead to: If successful, this technique could become a new standard for staging testicular cancer, helping doctors avoid unnecessary treatments and their side effects.
What could go wrong: This is a small, early feasibility study with only 44 participants. The technique may not achieve the desired 90% sensitivity, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

germ cell tumor Neoplasms, Germ Cell and Embryonal nongerminomatous germ cell tumor Nonseminomatous germ cell tumor seminoma testicular cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERM CELL TUMOR NONSEMINOMATOUS GERM CELL TUMOR SEMINOMA

Contacts and locations

Locations

University Hospital of Duesseldorf
RECRUITING

Düsseldorf, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.